Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Door County Cancer Center at Door County Memorial Hospital
mi
from
Sturgeon Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Door County Cancer Center at Door County Memorial Hospital
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Rocky Mountain Oncology
mi
from
Casper, WY
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Rocky Mountain Oncology
mi
from
Casper, WY
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients
Status: Enrolling
Updated:  10/23/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients
Status: Enrolling
Updated: 10/23/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients
Status: Enrolling
Updated:  10/23/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients
Status: Enrolling
Updated: 10/23/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated:  10/23/2017
New York University Langone Medical Center
mi
from
New York, NY
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated: 10/23/2017
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated:  10/23/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated: 10/23/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated:  10/23/2017
Rockefeller University
mi
from
New York, NY
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated: 10/23/2017
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated:  10/23/2017
Weill-Cornell Medical College
mi
from
New York, NY
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated: 10/23/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated:  10/23/2017
Lenox Hill Hospital
mi
from
New York, NY
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated: 10/23/2017
Lenox Hill Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated:  10/23/2017
North Shore University Hospital
mi
from
New York, NY
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated: 10/23/2017
North Shore University Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated:  10/23/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Status: Enrolling
Updated: 10/23/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Pediatric Brain Tumor Consortium
mi
from
Memphis, TN
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Pediatric Brain Tumor Consortium
mi
from
Memphis, TN
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Texas Children's Hospital
mi
from
Houston, TX
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated:  10/23/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Status: Enrolling
Updated: 10/23/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Miller Children's Hospital
mi
from
Long Beach, CA
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Miller Children's Hospital
mi
from
Long Beach, CA
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
A. I. duPont Hospital for Children
mi
from
Wilmington, DE
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
A. I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Children's Hospital of Southwest Florida at Lee Memorial
mi
from
Fort Myers, FL
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Children's Hospital of Southwest Florida at Lee Memorial
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Nemours Children's Clinic
mi
from
Jacksonville, FL
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
All Children's Hospital
mi
from
Saint Petersburg, FL
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Tampa General Hospital
mi
from
Tampa, FL
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Kapiolani Medical for Women and Children
mi
from
Honolulu, HI
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Kapiolani Medical for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Ochsner Clinic Foundation New Orleans
mi
from
New Orleans, LA
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Ochsner Clinic Foundation New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Dana-Farber Cancer Institute/Boston Children's Hospital
mi
from
Boston, MA
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Dana-Farber Cancer Institute/Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Mercy Children's Hospital
mi
from
Toledo, OH
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Mercy Children's Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  10/25/2017
Randall Children's Hospital at Legacy Emanuel
mi
from
Portland, OR
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 10/25/2017
Randall Children's Hospital at Legacy Emanuel
mi
from
Portland, OR
Click here to add this to my saved trials